Drug repurposing for COVID-19 based on an integrative meta-analysis of SARS-CoV-2 induced gene signature in human airway epithelium.
Drug repurposing has the potential to bring existing de-risked drugs for effective intervention in an ongoing pandemic-COVID-19 that has infected over 131 million, with 2.8 million people succumbing to the illness globally (as of April 04, 2021). We have used a novel `gene signature'-based drug...
Main Authors: | Rajaneesh K Gupta, Enyinna L Nwachuku, Benjamin E Zusman, Ruchira M Jha, Ava M Puccio |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2021-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0257784 |
Similar Items
-
B-Cell Lymphoma 2 (Bcl-2) and Regulation of Apoptosis after Traumatic Brain Injury: A Clinical Perspective
by: Hansen Deng, et al.
Published: (2020-06-01) -
The Transcriptome Landscape of the In Vitro Human Airway Epithelium Response to SARS-CoV-2
by: Said Assou, et al.
Published: (2023-07-01) -
Ultrastructural insight into SARS-CoV-2 entry and budding in human airway epithelium
by: Andreia L. Pinto, et al.
Published: (2022-03-01) -
The interplay between the airway epithelium and tissue macrophages during the SARS-CoV-2 infection
by: Emilia Barreto-Duran, et al.
Published: (2022-10-01) -
Inhibition of SARS-CoV-2 infection in human airway epithelium with a xeno-nucleic acid aptamer
by: Niayesh Razi, et al.
Published: (2023-11-01)